The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1052
May 7, 1999
View Complete Issue         Table of Contents 2019 
Cilostazol for Intermittent Claudication
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cilostazol for Intermittent Claudication
May 7, 1999 (Issue: 1052)
Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cilostazol for Intermittent Claudication
Article code: 1052b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.